Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate in Patients With Essential Hypertension

NCT02612298 is registered in ClinicalTrials.gov with Marubeni Pharmaceuticals (Suzhou) Co., Ltd. as lead sponsor.

NCT NCT02612298
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02612298 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate in Patients With Essential Hypertension
Lead sponsor
Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Phase
Phase 4
Overall status
Completed
Start date
August 31, 2015
Completion date
September 13, 2018
Enrollment
198 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

essential hypertension